PORTOLA VALLEY, Calif., June 4 — Spectros Corporation
(Portola Valley, CA) signed an agreement with Caliper Life Sciences
allowing Caliper limited access to certain Spectros optical imaging
technologies for undisclosed terms. “We are pleased that Caliper Life
Sciences has recognized the benefit and value of the broad and early
optical biotechnology here at Spectros,” notes David Benaron, CEO.
Spectros and its affiliates have over 70 patents in the U.S., Europe,
and Japan assigned or in-licensed, forming one of the largest biophotonics
intellectual property collections. Spectros core patents cover optical
spectroscopy, fluorimetry, and imaging for use in blood analysis,
contrast-targeted cancer surgery, lab-on-chip systems, and benchtop life
sciences equipment, “Given the depth of our biophotonics patent portfolio,
we anticipate significant top-line growth for our licensing program,”
commented David Benaron, CEO. Red Herring predicts that the total market
for optical products in molecular detection, molecular imaging, and
treatment guidance will grow to over $12 billion annually over the next
ABOUT SPECTROS: Spectros markets and licenses advanced molecular
sensing and imaging devices that shed light on ischemia and cancer.
T-Stat(R), the Company’s lead product, is FDA-approved and marketed in the
U.S. and Europe for detection of ischemia, an insufficient blood flow to
tissue. Spectros is co-developing an optical breast cancer screening
device, currently in clinical trials, in conjunction with the University of
California, the University of Pennsylvania, and others. Spectros
out-licenses optical technology separate from these clinical product lines.
Spectros is a venture-capital supported private concern.
(Note: Forward-looking statements are intended as a guide only, and do
not constitute an offer for investment nor a guarantee of future returns.
Some applications described above are for investigational use only, and
have not been reviewed and/or approved by the FDA.)